Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) — Working Capital to Net Assets Ratio
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Working Capital to Net Assets ratio of 60.5% as of September 2025. Working capital of CN¥1.65 Billion (current assets of CN¥1.77 Billion minus current liabilities of CN¥119.95 Million) is measured against net assets of CN¥2.73 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how many days can Zhejiang Wolwo Bio-Pharmaceutical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Working Capital to Net Assets (2009–2024)
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 16 annual periods from 2009 to 2024. As of September 2025, the ratio stands at 60.5%, reflecting working capital of CN¥1.65 Billion against net assets of CN¥2.73 Billion CNY. For the complete balance sheet picture, see balance sheet size of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd.
Annual Working Capital to Net Assets for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Zhejiang Wolwo Bio-Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 59.7% | CN¥1.47 Billion | CN¥2.46 Billion | CN¥1.65 Billion | CN¥182.58 Million | ▼ -0.7 pp |
| 2023 | 60.5% | CN¥1.39 Billion | CN¥2.30 Billion | CN¥1.57 Billion | CN¥177.04 Million | ▼ -7.3 pp |
| 2022 | 67.8% | CN¥1.37 Billion | CN¥2.03 Billion | CN¥1.48 Billion | CN¥102.75 Million | ▼ -0.9 pp |
| 2021 | 68.7% | CN¥1.23 Billion | CN¥1.80 Billion | CN¥1.34 Billion | CN¥108.00 Million | ▼ -4.3 pp |
| 2020 | 73.0% | CN¥1.12 Billion | CN¥1.53 Billion | CN¥1.17 Billion | CN¥55.42 Million | ▼ -0.2 pp |
| 2019 | 73.2% | CN¥989.97 Million | CN¥1.35 Billion | CN¥1.05 Billion | CN¥60.03 Million | ▲ +0.5 pp |
| 2018 | 72.7% | CN¥724.04 Million | CN¥995.42 Million | CN¥781.66 Million | CN¥57.62 Million | ▼ -3.9 pp |
| 2017 | 76.7% | CN¥614.30 Million | CN¥801.26 Million | CN¥656.50 Million | CN¥42.20 Million | ▼ 0.0 pp |
| 2016 | 76.7% | CN¥502.75 Million | CN¥655.58 Million | CN¥539.21 Million | CN¥36.46 Million | ▼ -2.2 pp |
| 2015 | 78.9% | CN¥459.65 Million | CN¥582.91 Million | CN¥484.28 Million | CN¥24.63 Million | ▼ -5.0 pp |
| 2014 | 83.9% | CN¥430.72 Million | CN¥513.55 Million | CN¥446.92 Million | CN¥16.20 Million | ▲ +11.2 pp |
| 2013 | 72.7% | CN¥183.05 Million | CN¥251.92 Million | CN¥195.08 Million | CN¥12.04 Million | ▲ +2.7 pp |
| 2012 | 70.0% | CN¥126.89 Million | CN¥181.38 Million | CN¥134.85 Million | CN¥7.96 Million | ▲ +8.8 pp |
| 2011 | 61.2% | CN¥78.06 Million | CN¥127.61 Million | CN¥94.99 Million | CN¥16.92 Million | ▲ +15.4 pp |
| 2010 | 45.8% | CN¥41.41 Million | CN¥90.44 Million | CN¥57.95 Million | CN¥16.54 Million | ▼ -17.1 pp |
| 2009 | 62.9% | CN¥70.40 Million | CN¥111.89 Million | CN¥75.47 Million | CN¥5.07 Million | — |